BALANCE: Olezarsen for Familial Chylomicronemia Syndrome

Olezarsen is an investigational drug that tackles triglycerides by blocking the production of apolipoprotein C-III (apoC3). ApoC3 normally hinders the liver’s ability to remove triglycerides from the blood. By reducing apoC3, Olezarsen allows the liver to work more effectively, lowering triglyceride levels. This can significantly reduce the risk of pancreatitis, a dangerous condition caused by high triglyceride levels in the blood.

STEP: Heart Failure in Obesity & Diabetes

Semaglutide benefits obesity-related heart failure in type 2 diabetes, improving symptoms and aiding weight loss. The STEP trial evaluated the effects of semaglutide (Ozempic or Wegovy) 2.4 mg weekly in participants with heart failure, obesity, and type 2 diabetes. Patients received either semaglutide or placebo for 52 weeks.

MAESTRO: First Treatment for NASH

Rezdiffra (Resmetirom), an oral medication targeting the liver and selective for thyroid hormone receptor β, demonstrated promising results. At doses of 80mg and 100mg, it achieved NASH resolution in 25% and 30% of participants, respectively, compared to just 10% in the placebo group.

SELECT: Obesity & Heart Health

Semaglutide, marketed as Ozempic or Wegovy and administered at a weekly dosage of 2.4 mg, has demonstrated a noteworthy reduction in cardiovascular events by 20% among non-diabetic individuals with obesity. Most participants had a diagnosis of prediabetes and a history of either myocardial infarction (MI) or stroke at the beginning of the study.

BrigHTN: Baxdrostat for Resistant Hypertension

Inhibiting aldosterone synthase presents a promising approach to treating hypertension. However, it is key to ensure selective inhibition to avoid compromising cortisol production. Recently, researchers have identified Baxdrostat as a highly selective AS inhibitor that does not interfere with cortisol synthesis. The specificity of Baxdrostat in inhibiting aldosterone synthase over cortisol synthase is 100:1

FIDELIO: Type 2 Diabetes & CKD

Kerendia (Finerenone) is an oral non-steroidal mineralocorticoid receptor (MR) antagonist. Excessive activation of mineralocorticoid receptors can result in hypertension, fluid retention, and cardiovascular harm, all of which have been directly linked to the deterioration of kidney function.

ORION: Gene Silencing, PCSK9 & LDL Cholesterol

Leqvio (Inclisiran) has received FDA approval as an additional therapy to diet and maximally tolerated statin medications for adults diagnosed with either heterozygous familial hypercholesterolemia (HeFH) or severe ASCVD who require further reduction of LDL cholesterol.